1AI
ALGORAE PHARMA ORDINARYAlgorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
1AI
1AI
ALGORAE PHARMA ORDINARY
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 1 Sept | — | — |
| 31 Aug | — | — |
| 28 Aug | — | — |
| 27 Aug | 0.00% | — |
| 26 Aug | 0.00% | — |
| 25 Aug | 0.00% | — |
| 24 Aug | 0.00% | — |
| 21 Aug | 0.00% | — |
| 20 Aug | 0.00% | — |
| 19 Aug | 0.00% | — |
| 18 Aug | 0.00% | — |
| 17 Aug | 0.00% | — |
Algorae Pharma (1AI) Short Interest Summary
Algorae Pharma (1AI) currently has 0.00% of its shares sold short (17 thousand shares, worth approximately $0K), based on ASIC short position data reported on 27 August 2026 (T+4 reporting lag). That makes 1AI the #643 most shorted stock on the ASX most shorted list. Short interest in 1AI is up 0.00% over the past week and up 0.00% over the past month. 1AI is part of the Health Care sector on the ASX.
Recent 1AI Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 27 Aug 2026 | 0.00% | 0.0M | $0.01 |
| 26 Aug 2026 | 0.00% | 0.0M | $0.01 |
| 25 Aug 2026 | 0.00% | 0.0M | $0.01 |
| 24 Aug 2026 | 0.00% | 0.0M | $0.01 |
| 21 Aug 2026 | 0.00% | 0.0M | $0.01 |
| 20 Aug 2026 | 0.00% | 0.0M | $0.01 |
| 19 Aug 2026 | 0.00% | 0.0M | $0.01 |
| 18 Aug 2026 | 0.00% | 0.0M | $0.01 |
| 17 Aug 2026 | 0.00% | 0.0M | $0.01 |
| 14 Aug 2026 | 0.00% | 0.0M | $0.01 |
1AI Short Selling — Frequently Asked Questions
What is Algorae Pharma (1AI)'s current short interest?
Algorae Pharma (1AI) currently has a short interest of 0.00% of total shares outstanding. This means 0.00% of 1AI's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is 1AI heavily shorted on the ASX?
1AI has a relatively low short interest of 0.00%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for 1AI investors?
Short interest in 1AI shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.00%, 1AI's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this 1AI short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for 1AI.